U.S. Dermatology Update eNewsletter
October 2021

FDA Approves Ruxolitinib Cream for Treatment of Atopic Dermatitis
The FDA announced the approval of Opzelura (ruxolitinib) cream for the short-term and noncontinuous chronic treatment of mild-to-moderate atopic dermatitis in nonimmunocompromised patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Read more.


Ceramide-Containing Skincare Lessens Dryness and Erythema in Acne Patients
Data from a presentation at the recent European Academy of Dermatology and Venerology Congress's virtual meeting revealed that the use of ceramide-containing skincare products in a daily skincare routine reduced dryness and erythema caused by the use of topical acne medications. Read more.

Enhancing the Quality, Safety, and Efficacy of Sunscreens
The FDA announced its goals of enhancing the quality, safety, and efficacy of sunscreens as a part of its implementation of new authorities for certain nonprescription drugs. The press release stated that although in the short term these new authorities basically maintain status quo marketing conditions for these sunscreens, the agency proposed updates to sun protection factor, product labeling, and other provisions. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App